C-TRACT | FMD Registry | PAUSE ER | RIETE | STRIDE |
C-TRACT: Chronic Venous Thrombosis: Relief with Adjunctive Catheter-Directed Therapy
Aims: The purpose of this study is to determine if the use of image-guided, endovascular therapy (EVT) is an effective strategy to reduce post thrombotic syndrome (PTS) disease severity and improve quality of life in patients with established disabling iliac-obstructive post thrombotic syndrome (DIO-PTS).
Diagnosis: Illiac obstructive post thrombotic syndrome
Principal Investigator/s: Alfonso Tafur, MD
IRB Approval Number: EH19-245
Sponsor: Washington University School of Medicine
Contact: Interested patients may contact Marisa Durante at 847.570.2125 or email mdurante@northshore.org
Open to Enrollment: Yes
FMD Registry: The U.S. Registry for Fibromuscular Dysplasia
Aims: The purpose of this registry is to gather real-world information and about Fibromuscular Dysplasia (FMD). By analyzing patterns and trends found within the registry, physicians may be able to learn more about this condition and ultimately improve the treatment of future FMD patients.
Diagnosis: Patients with established diagnosis of Fibromuscular Dysplasia
Principal Investigator/s: Kambiz Zorriasateyn, MD
IRB Approval Number: EH21-149
Sponsor: Cleveland Clinic
Contact: Interested patients may contact Lucas Wathen at 847.570.2099 or email lwathen@northshore.org
Open to Enrollment: Yes
Perioperative Anticoagulant Use for Surgery Evaluation-in the Emergency Registry (PAUSE-ER) Study. Patients Receiving Warfarin or a Direct Oral Anticoagulant (DOAC – apixaban, dabigatran, edoxaban or rivaroxaban) and Require an Urgent/Emergency Surgery or Procedure: A Prospective Registry Study
Aims: The proposed pre- and post-procedure management protocol is standardized but adjusted, according to patients’ renal function and the surgery/procedure-related bleed risk, to optimize patient safety and does not include heparin bridging.
Diagnosis: No diagnoses require but has urgent procedure/surgery, currently taking NOAC drugs
Principal Investigator/s: Alfonso Tafur, MD
IRB Approval Number: EH20-083
Sponsor: Abiomed
Contact: Interested patients may contact Marisa Durante at 847.570.2125 or email mdurante@northshore.org
Open to Enrollment: Yes
RIETE: Computerized Registry of Patients with Venous Thromboembolism
Aims: The RIETE Registry is a multidisciplinary project aimed at providing information on the Internet that helps physicians improve their knowledge on the natural history of thromboembolic disease, particularly in those subgroups of patients who are usually not recruited in randomized clinical trials (pregnant women, elderly patients, disseminated cancer, severe renal insufficiency, patients with contraindications to anticoagulation therapy or extreme body weight), with the purpose of decreasing mortality, frequency of thromboembolic recurrences, as well as bleeding complications and arterial events. RIETE also aims to create predictive scores that help physicians to better identify patients with high risk of developing some of these complications.
Diagnosis: Acute deep vein thrombosis (DVT), pulmonary embolism (PE) and/or superficial venous thrombosis (SVT).
Principal Investigator/s: Alfonso Tafur, MD
IRB Approval Number: EH11-337
Sponsor: Manuel Monreal, Foundation for the study of venous thromboembolism (VTE) diseases
Contact: Interested patients may contact Marisa Durante at 847.570.2125 or email mdurante@northshore.org
Open to Enrollment: Yes
STRIDE: A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes (STRIDE)
Aims: This study will be looking at the effect of Semaglutide on walking ability compared with placebo in people with peripheral arterial disease and type 2 diabetes.
Diagnosis: Patients with established diagnosis of Peripheral Arterial Disease
Principal Investigator/s: Arman Qamar, MD
IRB Approval Number: EH21-137
Sponsor: NovoNordisk
Contact: Interested patients may contact Caitlin Nagy at 224.251.4976 or email cnagy@northshore.org
Open to Enrollment: Yes